172 related articles for article (PubMed ID: 15310398)
1. Is drug-induced toxicity a good predictor of response to neo-adjuvant chemotherapy in patients with breast cancer?--a prospective clinical study.
Chintamani ; Singhal V; Singh JP; Lyall A; Saxena S; Bansal A
BMC Cancer; 2004 Aug; 4():48. PubMed ID: 15310398
[TBL] [Abstract][Full Text] [Related]
2. Estimation of BCL-2 protein in carcinoma of the breast and its clinical correlation in locally advanced breast cancer.
Aggarwal H; Lubana PS; Jain DK; Mathur RK
J Cancer Res Ther; 2007; 3(4):207-10. PubMed ID: 18270395
[TBL] [Abstract][Full Text] [Related]
3. The efficacy and safety of neoadjuvant chemotherapy +/- letrozole in postmenopausal women with locally advanced breast cancer: a randomized phase III clinical trial.
Mohammadianpanah M; Ashouri Y; Hoseini S; Amadloo N; Talei A; Tahmasebi S; Nasrolahi H; Mosalaei A; Omidvari S; Ansari M; Mosleh-Shirazi MA
Breast Cancer Res Treat; 2012 Apr; 132(3):853-61. PubMed ID: 22002564
[TBL] [Abstract][Full Text] [Related]
4. The nuclear transcription factor kappaB/bcl-2 pathway correlates with pathologic complete response to doxorubicin-based neoadjuvant chemotherapy in human breast cancer.
Buchholz TA; Garg AK; Chakravarti N; Aggarwal BB; Esteva FJ; Kuerer HM; Singletary SE; Hortobagyi GN; Pusztai L; Cristofanilli M; Sahin AA
Clin Cancer Res; 2005 Dec; 11(23):8398-402. PubMed ID: 16322301
[TBL] [Abstract][Full Text] [Related]
5. Role of neo-adjuvant chemotherapy in locally advanced breast cancer.
Akhtar M; Akulwar V; Kulkarni A; Bansal A
Indian J Cancer; 2015; 52(3):286-9. PubMed ID: 26905112
[TBL] [Abstract][Full Text] [Related]
6. Role of p-glycoprotein expression in predicting response to neoadjuvant chemotherapy in breast cancer--a prospective clinical study.
Chintamani ; Singh JP; Mittal MK; Saxena S; Bansal A; Bhatia A; Kulshreshtha P
World J Surg Oncol; 2005 Sep; 3():61. PubMed ID: 16164742
[TBL] [Abstract][Full Text] [Related]
7. Randomized trial comparing neo-adjuvant versus adjuvant chemotherapy in operable locally advanced breast cancer (T4b N0-2 M0).
Deo SV; Bhutani M; Shukla NK; Raina V; Rath GK; Purkayasth J
J Surg Oncol; 2003 Dec; 84(4):192-7. PubMed ID: 14756429
[TBL] [Abstract][Full Text] [Related]
8. Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast.
von Minckwitz G; Sinn HP; Raab G; Loibl S; Blohmer JU; Eidtmann H; Hilfrich J; Merkle E; Jackisch C; Costa SD; Caputo A; Kaufmann M;
Breast Cancer Res; 2008; 10(2):R30. PubMed ID: 18380893
[TBL] [Abstract][Full Text] [Related]
9. Apoptosis and proliferation as predictors of chemotherapy response in patients with breast carcinoma.
Chang J; Ormerod M; Powles TJ; Allred DC; Ashley SE; Dowsett M
Cancer; 2000 Dec; 89(11):2145-52. PubMed ID: 11147583
[TBL] [Abstract][Full Text] [Related]
10. Sentinel lymph node biopsy using dye alone method is reliable and accurate even after neo-adjuvant chemotherapy in locally advanced breast cancer--a prospective study.
Chintamani ; Tandon M; Mishra A; Agarwal U; Saxena S
World J Surg Oncol; 2011 Feb; 9():19. PubMed ID: 21396137
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant chemotherapy with infusional 5-fluorouracil, adriamycin and cyclophosphamide (iFAC) in locally advanced breast cancer: an early response predicts good prognosis.
Moon YW; Rha SY; Jeung HC; Yang WI; Suh CO; Chung HC
Ann Oncol; 2005 Nov; 16(11):1778-85. PubMed ID: 16091429
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant chemotherapy for local advanced breast cancer with stage IIIB.
Kim R; Osaki A; Tanabe K; Toge T
Oncol Rep; 2004 Jun; 11(6):1265-72. PubMed ID: 15138565
[TBL] [Abstract][Full Text] [Related]
13. Treatment response to preoperative anthracycline-based chemotherapy in locally advanced breast cancer: the relevance of proliferation and apoptosis rates.
Kanjer K; Tatić S; Nešković-Konstantinović Z; Abu Rabi Z; Nikolić-Vukosavljević D
Pathol Oncol Res; 2013 Jul; 19(3):577-88. PubMed ID: 23526163
[TBL] [Abstract][Full Text] [Related]
14. Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: a study by the GEICAM group.
Martin M; Villar A; Sole-Calvo A; Gonzalez R; Massuti B; Lizon J; Camps C; Carrato A; Casado A; Candel MT; Albanell J; Aranda J; Munarriz B; Campbell J; Diaz-Rubio E;
Ann Oncol; 2003 Jun; 14(6):833-42. PubMed ID: 12796019
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial.
von Minckwitz G; Kümmel S; Vogel P; Hanusch C; Eidtmann H; Hilfrich J; Gerber B; Huober J; Costa SD; Jackisch C; Loibl S; Mehta K; Kaufmann M;
J Natl Cancer Inst; 2008 Apr; 100(8):542-51. PubMed ID: 18398097
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant chemotherapy in locally advanced breast cancer.
Singh G; Singh DP; Gupta D; Muralikrishna BV
J Surg Oncol; 1996 Jan; 61(1):38-41. PubMed ID: 8544458
[TBL] [Abstract][Full Text] [Related]
17. Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial.
Leonard RC; Lind M; Twelves C; Coleman R; van Belle S; Wilson C; Ledermann J; Kennedy I; Barrett-Lee P; Perren T; Verrill M; Cameron D; Foster E; Yellowlees A; Crown J;
J Natl Cancer Inst; 2004 Jul; 96(14):1076-83. PubMed ID: 15265969
[TBL] [Abstract][Full Text] [Related]
18. Early response to neo-adjuvant chemotherapy in carcinoma of the breast predicts both successful breast-conserving surgery and decreased risk of ipsilateral breast tumor recurrence.
Ishitobi M; Komoike Y; Motomura K; Koyama H; Inaji H
Breast J; 2010; 16(1):9-13. PubMed ID: 19929889
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial.
Francis P; Crown J; Di Leo A; Buyse M; Balil A; Andersson M; Nordenskjöld B; Lang I; Jakesz R; Vorobiof D; Gutiérrez J; van Hazel G; Dolci S; Jamin S; Bendahmane B; Gelber RD; Goldhirsch A; Castiglione-Gertsch M; Piccart-Gebhart M;
J Natl Cancer Inst; 2008 Jan; 100(2):121-33. PubMed ID: 18182617
[TBL] [Abstract][Full Text] [Related]
20. Pharmacoproteomic analysis of prechemotherapy and postchemotherapy plasma samples from patients receiving neoadjuvant or adjuvant chemotherapy for breast carcinoma.
Pusztai L; Gregory BW; Baggerly KA; Peng B; Koomen J; Kuerer HM; Esteva FJ; Symmans WF; Wagner P; Hortobagyi GN; Laronga C; Semmes OJ; Wright GL; Drake RR; Vlahou A
Cancer; 2004 May; 100(9):1814-22. PubMed ID: 15112261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
